Matthew K. Fust, Director at Crinetics Pharmaceuticals, Inc. (CRNX), sold 3,500 shares at $22.50 ($79K) on 2019-12-16, disclosed to the SEC on 2019-12-18.
Open-market sale of $79k CRNX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| CRNX | SELL | 2024-03-22 | $2.1M | — | Filing → |
| RARE | SELL | 2024-03-11 | $859K | — | Filing → |
| CRNX | SELL | 2022-07-15 | $119K | — | Filing → |